Quick Answer
Kiniksa Pharmaceuticals International, plc reported Diluted EPS of $0.75 per share for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.75 | +225.0% |
| 2024 | -$0.60 | -400.0% |
| 2023 | $0.20 | -92.3% |
| 2022 | $2.60 | +213.0% |
| 2021 | -$2.30 | +11.9% |
| 2020 | -$2.61 | +12.7% |
| 2019 | -$2.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.23 | +227.8% | +0.0% |
| June 30, 2025 | $0.23 | +483.3% | +109.1% |
| March 31, 2025 | $0.11 | +144.0% | +161.1% |
| September 30, 2024 | -$0.18 | +10.0% | -200.0% |
| June 30, 2024 | -$0.06 | -128.6% | +76.0% |
| March 31, 2024 | -$0.25 | -38.9% | -25.0% |
| September 30, 2023 | -$0.20 | -106.3% | -195.2% |
| June 30, 2023 | $0.21 | +172.4% | +216.7% |
- Kiniksa Pharmaceuticals International, plc showed an increase of +225.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Kiniksa Pharmaceuticals International, plc’s diluted eps has grown by 125.1% (from $2.99 per share (loss) to $0.75 per share).
- The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: